Does Medicaid Cover Wegovy, Ozempic, or Zepbound in 2026? State-by-State Coverage Map & Appeal Guide

Most Medicaid plans still do not pay for Wegovy, Ozempic, or Zepbound when they are prescribed strictly for weight loss in 2026. Thirteen states have carved out limited coverage when your body-mass index (BMI) meets strict cut-offs and at least one weight-related condition is documented, while all 50 states must cover these same drugs for FDA-approved diabetes or cardiovascular indications. If you live in a non-covering state or get denied after prior authorization, you can still lower your out-of-pocket cost by filing a structured appeal and comparing cash prices through Rx.com’s discount card.

• Only 13 of 50 Medicaid programs cover GLP-1s for obesity as of January 2026, according to Kaiser Family Foundation research.(kff.org)
• Coverage states cap eligibility at a BMI of ≥35 kg/m² or ≥30 kg/m² with at least one comorbidity such as hypertension or sleep apnea.(kff.org)
• All states require a prior authorization (PA) packet that proves six months of failed lifestyle therapy and includes the prescribing provider’s attestation.
• Medi-Cal, the nation’s largest Medicaid program, removed weight-loss indications for Wegovy and Zepbound on January 1 2026 to control drug spend.(medi-calrx.dhcs.ca.gov)
• Denied claims can be appealed: the success rate rises to 48 percent when metabolic comorbidities and cardiovascular risk scores are attached to the letter.(kff.org)

What Medicaid GLP-1 Coverage Looks Like in 2026

Medicaid must cover Ozempic and Mounjaro when they are prescribed for type 2 diabetes, because federal law requires coverage of FDA-approved diabetes drugs. The same molecule (semaglutide or tirzepatide) used for weight loss, however, is legally optional. That is why Wegovy and Zepbound sit in a grey zone.

Definition: A “covered” obesity drug means your state will pay for it if you meet published BMI and comorbidity rules, complete six months of monitored lifestyle therapy, and receive prior authorization. Simply having Medicaid does not guarantee payment.

In 2026 states faced tighter budgets after the federal Medicaid cuts in the 2025 reconciliation law. Many responded by restricting or removing GLP-1 coverage for weight loss. Medi-Cal, for example, issued a State Plan Amendment excluding weight-loss indications effective January 1 2026.(medi-calrx.dhcs.ca.gov)

2026 State-by-State Medicaid Coverage Table

The table below summarizes each state’s policy for Wegovy or Zepbound when prescribed for obesity. “Diabetes/Cardio OK” means the drug is still covered when used for FDA-approved diabetes or cardiovascular indications.

The 13 “Yes” states match the latest Kaiser Family Foundation count and may expand if the CMS BALANCE model succeeds in negotiating lower net prices.(kff.org)

Why Medicaid Denies GLP-1 Claims

Most denials boil down to missing documentation or a mismatch between the prescription and the state’s published criteria.

Common denial codes: Reject 70 (product/service not covered), Reject 75 (PA required), and Reject 79 (invalid DAW code) are universal. Medi-Cal specifically attaches “GLP-1s for weight loss are not covered” to Wegovy claims dated on or after January 1 2026.(medi-calrx.dhcs.ca.gov)

Top documentation gaps:

• Incomplete lifestyle therapy notes: States need six months of dietitian or physician-supervised weight-loss attempts.
• Missing comorbidity labs: Attach the most recent A1C, blood pressure log, or sleep study to prove comorbid risk.
• Wrong NDC code: Wegovy HD 7.2 mg pens use new National Drug Codes effective May 2026.(dailymed.nlm.nih.gov)

How to Win an Appeal After Denial

Every Medicaid program must offer at least one level of appeal within 60 days of a denial notice. Success increases when the letter precisely addresses the denial code and cites medical necessity.

Step-by-step appeal template:

1. Request the denial letter (hard copy or portal) to identify the exact reason code.
2. Gather evidence such as BMI trajectory, comorbidity diagnoses, lab values, and documentation of six months of lifestyle therapy.
3. Write the appeal letter:
   Subject: Appeal of PA Denial 70 for Wegovy (NDC 55513-202-01)
   Body: State the beneficiary’s name, Medicaid ID, and date of denial. Explain medical necessity: “The patient’s BMI is 38 kg/m² with uncontrolled hypertension (ICD-10 I10) despite six months of DASH diet and 5% weight loss plateau.” Cite FDA labeling for Wegovy’s cardiovascular risk-reduction indication. Attach supporting records.
4. Submit within deadline via the address or portal listed in the denial notice. Keep proof of receipt.
5. Escalate to fair hearing if the first-level appeal fails. Many states decide fair hearings within 60 days. New York, for example, must issue a determination in 30 days under the revised appeals timeframe rule.(health.ny.gov)

Appeal turnaround times will shorten further in 2027 when the CMS Interoperability and Prior Authorization final rule takes full effect.(health.ny.gov)

Alternatives When Medicaid Will Not Pay

Coverage gaps do not have to end your treatment journey.

Use a free Rx.com discount card: The average cash price for a 2 mg Ozempic pen fell to $743 in August 2026 after manufacturer price concessions. Many patients pay $699 or less at major retail chains when they show the card at checkout.

Compare Wegovy vs compounded semaglutide: Compounded versions cost as little as $199 per month according to our Cheapest GLP-1 2026 price table. Compounded drugs are not FDA-approved, so weigh risks carefully and confirm the pharmacy’s 503A status.

Switch to orforglipron (oral GLP-1): Early 2026 trial data suggest similar weight loss with a projected list price 28 percent lower than injectable semaglutide. See our orforglipron vs Rybelsus guide for details.